Background South America has a higher incidence of gestational trophoblastic disease than North America or Europe, but whether this impacts chemotherapy outcomes is unclear. The purpose of this study was to evaluate outcomes among women with high-risk gestational trophoblastic neoplasia (GTN) treated at trophoblastic disease centers in developing South American countries.
Methods This retrospective cohort study included patients with high-risk GTN treated in three trophoblastic disease centers in South America (Botucatu and Rio de Janeiro, Brazil, and Buenos Aires, Argentina) from January 1990 to December 2014. Data evaluated included demographics, clinical presentation, FIGO stage, WHO prognostic risk score, and treatment-related information. The primary treatment outcome was complete sustained remission by 18 months following completion of therapy or death.
Results Among 1264 patients with GTN, 191 (15.1%) patients had high-risk GTN and 147 were eligible for the study. Complete sustained remission was ultimately achieved in 87.1% of cases overall, including 68.4% of ultra high-risk GTN (score ≥12). Early death (within 4 weeks of initiating therapy) was significantly associated with ultra high-risk GTN, occurring in 13.8% of these patients (p=0.003). By Cox’s proportional hazards regression, factors most strongly related to death were non-molar antecedent pregnancy (RR 4.35, 95% CI 1.71 to 11.05), presence of liver, brain, or kidney metastases (RR 4.99, 95% CI 1.96 to 12.71), FIGO stage (RR 3.14, 95% CI 1.52 to 6.53), and an ultra-high-risk prognostic risk score (RR 7.86, 95% CI 2.99 to 20.71). Median follow-up after completion of chemotherapy was 4 years. Among patients followed to that timepoint, the probability of survival was 90% for patients with high-risk GTN (score 7–11) and 60% for patients with ultra-high-risk GTN (score ≥12).
Conclusion Trophoblastic disease centers in developing South American countries have achieved high remission rates in high-risk GTN, but early deaths remain an important problem, particularly in ultra-high-risk GTN.
- gestational trophoblastic disease
- trophoblastic neoplasms
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors IM: conceived and designed the study, wrote the manuscript, audited data collected by MFSM from Botucatu Trophoblastic Disease Center (São Paulo State University). MM: identified and collected data from Botucatu Trophoblastic Disease Center (São Paulo State University) and from Rio de Janeiro Trophoblastic Diseases Center (Federal University of Rio de Janeiro Maternity School), wrote the manuscript. JR-F: helped with the analysis of the data from Rio de Janeiro Trophoblastic Diseases Center (Federal University of Rio de Janeiro Maternity School), contributed to the manuscript. MB: audited data collected by LACR from Durand Trophoblastic Disease Center in Buenos Aires (Carlos G. Durand Hospital), contributed to data analysis. GJ: helped with the analysis of the data from Durand Trophoblastic Disease Center in Buenos Aires (Carlos G. Durand Hospital), contributed to the manuscript. SO: helped with the analysis of the data from Carlos G. Durand Hospital, contributed to the manuscript. LR: reviewed the literature, collected and managed data from Durand Trophoblastic Disease Center in Buenos Aires (Carlos G. Durand Hospital). SYS: contributed to data analysis and interpretation. KE: conceived the analysis strategy, contributed to the manuscript. NH: contributed to data analysis and interpretation, critically revised the manuscript. AB: audited data collected by MFSM from Rio de Janeiro Trophoblastic Diseases Center (Federal University of Rio de Janeiro Maternity School). RB: supervised the study, critically revised the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.